The TAME trial and beyond (Dr. Nir Barzilai)

Dr. Nir Barzilai is the founding director of the Institute for Aging Research, the Nathan Shock Center of Excellence in the Basic Biology of Aging, and the Paul F. Glenn Center for the Biology of Human Aging Research at Albert Einstein College of Medicine of Yeshiva University. He is also the author of the book Age Later. Today, Dr. Nir brings his expertise to the podcast for a discussion regarding longevity and aging.

Nir starts the conversation with a discussion on the existing regulatory frameworks that create impediments to the longevity biotech sector such as the FDA regulations. He also explores the use of metformin in combating age-related diseases, the clinical trials surrounding metformin being carried out in the Longevity Biotech Association, dealing with members of  the government, and his perspective regarding what longevity biotech will be like in 5 years.

In this episode, you’ll learn the uses of metformin and its relation to age-related diseases and what Nir hopes to see in the longevity industry in years to come .

Episode Highlights:

• The existing regulatory frameworks that create impediments to the longevity biotech sector
• What is metformin and its relationship with age-related disease?
• Targeting aging with metformin — the TAME trial
• How other biomarkers would be tracked in the study
• The future of the trials and what is set to happen after it ends
• Examining the economics
• The mission of the Longevity Biotech Association
• The longevity industry in 5 years
• Challenges that come with conversing with the Government concerning longevity and aging

Quotes:

“Aging drives diseases and those diseases can be delayed.”

“If aging drives all diseases, then it's the mother of diseases.”

“After all, what are we trying to do? We are trying to prevent a cluster of age related diseases.”

“Even if metformin doubles in price because of demand, it's still going to be the cheapest drug in the pharmacy.”

“There are nine studies that show that people on metformin had less hospitalization, and less mortality from COVID if they were on metformin.”

“Science is not a bipartisan issue.”

“We need to extend the field and extend the actual funding to do it.”

Links:

Email questions, comments, and feedback to [email protected]

Translating Aging on Twitter: @bioagepodcast

BIOAGE Labs Website BIOAGELabs.com

BIOAGE Labs Twitter @bioagelabs

BIOAGE Labs LinkedIn

Dr. Nir Barzilai’s Twitter